Literature DB >> 24691708

Omalizumab: stepping outside our comfort zone to broaden the number of those who can benefit.

Mario Cazzola1, Andrea Segreti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24691708     DOI： 10.1007/s40265-014-0205-9

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  21 in total

Review 1.  Mechanisms of intrinsic asthma.

Authors:  Chris Corrigan
Journal:  Curr Opin Allergy Clin Immunol       Date:  2004-02

2.  Effects of omalizumab in non-atopic asthma: results from a Spanish multicenter registry.

Authors:  Luis Pérez de Llano; María Del Carmen Vennera; Francisco J Álvarez; Juan F Medina; Luis Borderías; Concha Pellicer; Héctor González; José A Gullón; Eva Martínez-Moragón; Carlos Sabadell; Soledad Zamarro; César Picado
Journal:  J Asthma       Date:  2013-01-28       Impact factor: 2.515

3.  Eligibility for treatment with omalizumab in Italy and Germany.

Authors:  Roland Buhl; Andrea Gili Marco; Daniel Cohen; Giorgio Walter Canonica
Journal:  Respir Med       Date:  2013-11-09       Impact factor: 3.415

4.  Omalizumab-induced decrease of FcξRI expression in patients with severe allergic asthma.

Authors:  Pascal Chanez; Cécile Contin-Bordes; Gilles Garcia; Christophe Verkindre; Alain Didier; Frédéric De Blay; Manuel Tunon de Lara; Patrick Blanco; Jean-François Moreau; Philip Robinson; Isabelle Bourdeix; Patrick Trunet; Vincent Le Gros; Marc Humbert; Mathieu Molimard
Journal:  Respir Med       Date:  2010-08-30       Impact factor: 3.415

5.  Monitoring free serum IgE in severe asthma patients treated with omalizumab.

Authors:  Stephanie Korn; Ina Haasler; Florian Fliedner; Gunther Becher; Pavel Strohner; Antonia Staatz; Christian Taube; Roland Buhl
Journal:  Respir Med       Date:  2012-08-11       Impact factor: 3.415

6.  Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study.

Authors:  Nicola A Hanania; Sally Wenzel; Karin Rosén; Hsin-Ju Hsieh; Sofia Mosesova; David F Choy; Preeti Lal; Joseph R Arron; Jeffrey M Harris; William Busse
Journal:  Am J Respir Crit Care Med       Date:  2013-04-15       Impact factor: 21.405

Review 7.  IgE and mast cells in allergic disease.

Authors:  Stephen J Galli; Mindy Tsai
Journal:  Nat Med       Date:  2012-05-04       Impact factor: 53.440

Review 8.  Omalizumab for severe asthma: efficacy beyond the atopic patient?

Authors:  Christian Domingo
Journal:  Drugs       Date:  2014-04       Impact factor: 9.546

9.  A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma.

Authors:  Gilles Garcia; Antoine Magnan; Raphaël Chiron; Cécile Contin-Bordes; Patrick Berger; Camille Taillé; Gilles Devouassoux; Frédéric de Blay; Louis-Jean Couderc; Alain Didier; Dermot S O'Callaghan; Pierre-Olivier Girodet; Isabelle Bourdeix; Vincent Le Gros; Marc Humbert
Journal:  Chest       Date:  2013-08       Impact factor: 9.410

10.  Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals.

Authors:  Go Takayama; Kazuhiko Arima; Taisuke Kanaji; Shuji Toda; Hiroyuki Tanaka; Shunsuke Shoji; Andrew N J McKenzie; Hiroichi Nagai; Takao Hotokebuchi; Kenji Izuhara
Journal:  J Allergy Clin Immunol       Date:  2006-04-27       Impact factor: 10.793
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.